Impel NeuroPharma jumps on U.S. approval for migraine treatment

IPI Legacy Liquidation Co

03/09/2021 15:51

** Shares of drug developer  IMPL.O  rise 18.3% to $27.35 in
morning trade, hitting a record high since their market debut in
April
    ** U.S. FDA approves Trudhesa, co's nasal spray to treat
migraine  urn:newsml:reuters.com:*:nL4N2Q52SO
    ** Co is positioning Trudhesa, which can be
self-administered to the bloodstream through the upper part of
the nasal canal, as an alternative to oral migraine treatments
    ** The FDA, however, has attached a strict warning to
Trudhesa, saying it carries risks of potential impaired blood
supply to the tissues when used in combination with certain
enzyme inhibitors used in steroids
    **  Co plans to commercially launch Trudhesa early October
    ** Including session's gains, stock up 82.3% since debut

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))